Louisiana State University has disclosed 5-HT2 receptor ligands reported to be useful for the treatment of anxiety, depression, asthma, chronic obstructive pulmonary disease (COPD), Alzheimer's disease, rheumatoid arthritis, chronic pain and post-stress traumatic disorder, among others.
Carna Biosciences Inc. and Sumitomo Pharma Co. Ltd. have identified dual-specificity tyrosine-(Y)-phosphorylation regulated kinase (DYRK) inhibitors reported to be useful for the treatment of cancer, depression, epilepsy, dementia, psychosis, thyroid and gastrointestinal disorders, among others.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Hangzhou Healzen Therapeutics Co. Ltd. has synthesized programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, infections, immunological and inflammatory disorders.
Researchers at Cincinnati Children's Hospital Medical Center, Kurome Therapeutics Inc. and the U.S. Department of Health and Human Services have disclosed IL-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Protego Biopharma Inc. has identified prodrugs of transthyretin (TTR; PALB) stabilizers acting as TTR aggregation and/or amyloid formation inhibitors reported to be useful for the treatment of familial amyloid polyneuropathy and familial amyloid cardiomyopathy.
PTC Therapeutics Inc. has synthesized heteroaryl compounds acting as huntingtin (HTT) (mutant) expression inhibitors reported to be useful for the treatment of Huntington's disease.
RSS